Search

Displaying results 2611 - 2620 of 2674 in total
  1. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012.

  2. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA … Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences.

    Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking Antibody
  3. Drug

    Galantamine

    go.drugbank.com/drugs/DB00674
    ApprovedInvestigational

    [A182993] The drug was approved by the FDA in 2001 for the treatment of mild to moderate dementia of the Alzheimer's type. … It also acts as an allosteric modulator of the nicotinic receptor, giving its dual mechanism of action clinical significance.

  4. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps

  5. Target

    Mitochondrial potassium channel ATP-binding subunit

    go.drugbank.com/bio_entities/BE0003673
    TransporterHumans

    ATP-binding subunit of the mitochondrial ATP-gated potassium channel (mitoK(ATP)) (PubMed:31435016). Together with pore-forming subunit CCDC51/MITOK of the mitoK(ATP) channel, mediates ATP-dependent potassium currents across the mitochon...

    Synonyms: Mitochondrial sulfonylurea-receptor
  6. Target

    Tumor necrosis factor ligand superfamily member 11

    go.drugbank.com/bio_entities/BE0003517
    TargetHumans

    Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions ...

    Synonyms: Receptor activator of nuclear factor kappa-B ligand
  7. Target

    Hepatocyte nuclear factor 4-alpha

    go.drugbank.com/bio_entities/BE0004019
    TargetHumans

    Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes (PubMed:30597922)...

    Synonyms: Nuclear receptor subfamily 2 group A member 1
  8. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    Simeprevir was approved by the FDA in November 2014 and is marketed under the brand name Olysio as oral tablets. … Sustained virologic response 12 weeks after planned end of treatment (SVR12) was achieved in 170/176 (97%) subjects without cirrhosis treated with 12 weeks simeprevir in combination with sofosbuvir (FDA

  9. Drug

    COVID-19 convalescent plasma

    go.drugbank.com/drugs/DB15692
    Investigational

    [L14333] Although there are no formal clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest

  10. Target

    Homeodomain-interacting protein kinase 3

    go.drugbank.com/bio_entities/BE0009448
    TargetHumans

    Enhances androgen receptor-mediated transcription. May act as a transcriptional corepressor for NK homeodomain transcription factors.

    Synonyms: Androgen receptor-interacting nuclear protein kinase